Drug intelligence / Profile preview

GB1211 and atezolizumab combination

Development stage: Unknown
Lead developer: Galecto
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

The combination of GB1211 and atezolizumab represents an innovative approach to cancer treatment, particularly for non-small cell lung cancer (NSCLC). This combination therapy pairs GB1211, an oral small molecule galectin-3 inhibitor developed by Galecto, with atezolizumab (Tecentriq®), a PD-L1 checkpoint inhibitor manufactured by Roche. The therapy aims to overcome resistance mechanisms to checkpoint inhibitors by addressing galectin-3-mediated interference with PD-1/PD-L1 binding, thereby restoring the effectiveness of checkpoint inhibitors.

Brand names: Tecentriq®

Targets

LGALS3 (Galectin-3)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on GB1211 and atezolizumab combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB1211 and atezolizumab combination.

Explore the full profile